Articles tagged with Blood Cancer
Researchers at Moffitt Cancer Center tested a 2-drug combination of sirolimus and tacrolimus to prevent acute grades of graft vs. host disease after blood cell transplantation, finding it more effective than another combination in preventing grades II-IV acute GVHD and moderate-severe chronic GVHD.
Researchers at UC San Diego have identified a new signal transduction pathway in alternative RNA splicing, which could lead to novel cancer drugs. The SRPK kinase plays a central role in regulating VEGF and controlling tumor growth.
A new analysis found that many adolescent and young adult cancer survivors experience chronic medical conditions, poor quality of life, and barriers to healthcare access. The study suggests that these negative behaviors are potentially modifiable through proper follow-up care and promotion of healthy habits.
Researchers at The Miriam Hospital found a 20 percent increased risk of developing blood cancers such as non-Hodgkin lymphoma, leukemia, and myeloma in patients with type 2 diabetes. Analyzing over 17,000 cases worldwide, they concluded that preventing diabetes may also lower the incidence of these malignancies.
A Phase III clinical trial found lenalidomide treatment decreased the risk of progressive myeloma or death in stem cell transplant patients, with a 63 percent reduction in disease progression risk. The study's results support the use of lenalidomide maintenance therapy after stem cell transplantation to improve patient outcomes.
Researchers at Vetmeduni Vienna have shown that chronic myeloid leukaemia (CML) and B-cell acute lymphoid leukaemia (B-ALL) arise from the same long-term haematopoietic stem cells. Understanding this finding is crucial for developing targeted therapies, as current treatments may not effectively target cancer stem cells.
Researchers present new methods for early lung cancer detection, including digital chest tomography and a blood test for BARD1 antibodies. These techniques have shown promising results in detecting lung cancer with high sensitivity and specificity.
A McGill University team has developed a new microarray technology that can accurately measure multiple proteins in a droplet of blood to detect breast cancer. The test, which uses a 'fingerprint' approach, showed promise in classifying patients with estrogen receptor-positive breast cancer.
Scientists at Fox Chase Cancer Center found that defects in ribosomal proteins can lead to blood and other cancers. Inactivating L22, a key protein, triggered changes in cell signaling pathways associated with inflammation, which may be targeted for cancer treatment.
Scientists will investigate the role of Myc oncoproteins and a specific mRNA-binding protein, TTP, in controlling tumor growth. The study aims to define mechanisms that could lead to the development of new anti-cancer drugs.
Researchers at Emory University identified a new function for p14 ARF, a gene that normally prevents cancer. The protein regulates tumor-induced angiogenesis, attracting new blood vessels to growing tumors. Restoring p14 ARF interferes with this process, suggesting a potential therapeutic target.
Blood cancers in pregnancy can lead to increased risk of blood clots and health complications for the mother. Termination is recommended at early stages, while cancer therapy is possible later. Progesterone-only contraceptives are considered safe for patients in long-term remission.
A new approach using an HIV drug has significantly reduced the incidence of graft-versus-host disease (GvHD) in blood cancer patients after allogeneic stem cell transplantation. Maraviroc dramatically reduced GvHD in organs such as the gut and liver without compromising the immune system.
A University of Rochester Medical Center study found that nearly 78% of cancer-related blood clots occur in outpatients during chemotherapy treatment. The study's findings suggest a shift towards outpatient care and the need for education and compliance to prevent blood clots.
Researchers at Dana-Farber Cancer Institute have created a peptide cocktail that sparks a stronger diverse immune response in laboratory culture than individual peptides. The combination of four antigenic peptides is believed to provide an effective therapeutic application for patients with multiple myeloma and related diseases.
A NYU Steinhardt professor has received a $720,000 grant to investigate the link between insulin and obesity-related cancers. Her research aims to understand how insulin affects cancer cell growth and development, particularly in relation to carbohydrate diets.
A new regimen of conditioning therapy before stem cell transplant has improved survival outcomes for older patients with hematologic malignancies. The study found that 5-year overall survival rates were around 35%, and progression-free survival rates were around 32%.
Patients aged 60-75 who received the mini-transplant experienced comparable survival rates across three age groups, with increased comorbidities and cancer aggressiveness affecting outcomes. The five-year survival rate was 35% for overall and 32% for disease-progression free
A recent study found that mutations in the SF3B1 gene are associated with a milder form of myelodysplastic syndromes (MDS) and better overall survival rates. The researchers also discovered a close relationship between the mutated gene and the presence of ring sideroblasts, abnormal precursors to red blood cells, which can cause anaemia.
A large study found that high blood pressure is associated with a higher risk of developing cancer and dying from the disease, particularly in men. The study analyzed data on blood pressure and cancer incidence and death in over 289,000 participants.
A genomic study identified the SF3B1 gene as frequently mutated in myelodysplasia, a precursor to leukaemia. The mutation is associated with ring sideroblasts and anaemia, leading to more straightforward diagnosis through a single blood test.
A study found that rescue workers and civilians exposed to World Trade Center dust had lower mortality rates compared to the NYC general population. Higher exposure levels were associated with increased mortality, particularly among those with high levels of WTC-related exposure.
A team co-led by Fred Hutchinson Cancer Research Center has been selected to participate in a National Cancer Institute-funded research consortium. The researchers will analyze proteins in blood associated with genetic alterations leading to cancer, with the goal of developing reliable blood tests for early detection and treatment.
23andMe's Myeloproliferative Neoplasms (MPN) research initiative aims to recruit 1,000 individuals with these rare blood cancers to participate in genetic analysis and online discussions. The program will advance research and create a community for those affected by MPNs.
Using a 'systems biology' approach, researchers identified proteins in the blood that change in abundance long before aggressive breast cancer is clinically detectable. The study found that host tissues respond to and amplify signals from tumor cells, leading to changes in blood-protein levels.
Research published in Occupational and Environmental Medicine suggests that growing up on a livestock farm is associated with an increased risk of developing blood cancers. The study found that those who grew up on poultry farms were three times more likely to develop a blood cancer.
Scientists have developed a tiny fiber-optic biosensor to detect elevated PSA levels in cases of breast cancer. The biosensor's sensitivity and specificity are comparable to those found in current screening methods for breast cancer.
A Duke University Medical Center research team has discovered new proteins in blood cells of patients with advanced prostate cancer and metastatic breast cancer. These proteins are associated with embryonic development and may help doctors gauge the progression or response to treatment more accurately.
A new molecular imaging agent has been developed to detect tumor angiogenesis, a process of rapid blood vessel growth associated with malignant cancers. The agent, which targets the CD105 protein biomarker, shows promising results in early studies, including high uptake by tumors in mice.
The National Institutes of Health has signed a research and development agreement with two non-profit organizations to develop potential clinical therapies for rare blood cancers. The collaboration aims to bridge the gap between basic research and human testing, with the goal of accelerating the delivery of improved therapies to patients.
A new study by the NYU Cancer Institute reveals that novel mutations in the Notch signaling pathway lead to the development of chronic myelomonocytic leukemia, a type of blood cancer. The study suggests potential targets for future therapies.
The TET1 enzyme controls gene activity during fetal development, preventing genes from being turned off at critical stages. By modifying methyl groups, TET1 acts as a safeguard to ensure normal cell growth and development.
A new microfluidic device, developed by MIT researchers, can detect single cancer cells in a blood sample and also identify viruses like HIV. This device has the potential to revolutionize cancer diagnosis and make it more accessible in developing countries.
A study of nearly 40 tumor genomes has yielded new and unexpected insights into the events that lead to multiple myeloma, a form of blood cancer. The researchers discovered genes never before associated with cancer, as well as genetic mutations disrupting common pathways that trigger cell change.
Research suggests that high levels of 'good' cholesterol (HDL) are associated with a reduced risk of bowel cancer. The association remains intact even after accounting for other factors such as inflammation, insulin resistance, and oxygen free radicals. HDL may alter the inflammatory process in some way, according to the study's authors.
A blood test can accurately detect biomolecular markers of bladder cancer risk linked to environmental exposures like cigarette smoke and industrial pollutants. The test measures methylation patterns in immune system cells, which are associated with an increased likelihood of disease.
A nine-year study found that high fiber intake was associated with a significantly reduced risk of total death, cardiovascular, infectious, and respiratory diseases in both men and women. Dietary fiber from whole plant foods, such as grains, was particularly beneficial.
Scientists discovered how stressed cells boost thrombin production, a key blood-clotting factor, which may be taken advantage by cancer cells. This process could explain why cancer patients are more likely to suffer from blood clots and septicaemia.
Researchers at the University of Wisconsin-Madison have successfully reprogrammed diseased blood cells into pluripotent stem cells, allowing for the observation of leukemia's onset in a laboratory dish. This breakthrough enables scientists to pinpoint the earliest stages of cancer development.
Researchers have developed PiggyBac, a genetic tool that can speed the discovery of novel genes involved in cancer. The system has identified new candidate cancer-causing genes and will complement advances in genomics and genetics of cancer.
A new study by UC Berkeley researchers found that children with acute lymphoid leukemia (ALL) had almost twice the chance of having been exposed to three or more X-rays compared to those without leukemia. The results differ slightly by region, with a modest increase associated with chest X-rays.
Researchers describe an indirect approach to reducing JAK2 activity by pharmacologically targeting HSP90. Inhibiting HSP90 normalized blood counts and improved survival in two mouse models of MPN, promoting JAK2 degradation in samples from patients with the disease.
A new risk prediction model for venous thromboembolism (VTE) in cancer patients has been developed, incorporating two new biomarkers. The model improves the classification of patients into different risk categories, with a significant increase in accurate predictions of VTE development.
Researchers at VCU Massey Cancer Center have discovered a new link between chronic inflammation and cancer, highlighting the importance of sphingosine-1-phosphate (S1P) in regulating inflammation. S1P is found to be a missing cofactor required for TRAF2's activity, which controls inflammation and cancer.
The study found a significantly higher incidence of MDS among seniors, with alarming rates of complications such as heart attacks, diabetes, and sepsis. The disease also proved to be costly to treat, with median Medicare bills exceeding $16,000
A new study found a link between chronic HBV and progression to cancers other than hepatocellular carcinoma, specifically Non-Hodgkin Lymphoma (NHL) and Cholangiocarcinoma. Higher levels of viral replication were associated with increased risk, indicating a potential causal effect.
Researchers at Fred Hutchinson Cancer Center have developed a method to expand stem/progenitor cells from cord blood units, resulting in successful treatment of high-risk leukemia. The expanded cells can rapidly give rise to white blood cells and other components of the blood system.
Scientists at Yale University have successfully used nanosensors to detect cancer biomarkers in whole blood for the first time. The new device can accurately measure concentrations of specific biomarkers with unprecedented precision, enabling faster and more reliable diagnoses.
A Yale University team developed a method to rapidly manipulate and sort cells in blood using magnetizable liquids. This technique could dramatically improve the speed and sensitivity of tests for cancer biomarkers, blood disorders, viruses, and other diseases.
A new study demonstrates advances in optimizing treatments and quality of life for patients with multiple myeloma. The research explores optimal induction therapies, advance care planning, and a potential new first-line therapy for non-Hodgkin lymphoma.
A study published in the Journal of the National Cancer Institute found that erythropoiesis-stimulating agents increase the risk of venous thromboembolism in cancer patients. The use of these agents, approved to reduce blood transfusions during chemotherapy, may outweigh benefits due to associated risks.
Researchers are developing innovative treatments to starve cancer cells of glucose, a strategy that has shown promising results in breast and colon cancer cases. RNA interference is also being explored as a gene therapy approach to block genes involved in cancer growth, with significant progress made in administering these medicines.
Researchers at Fox Chase Cancer Center discovered the Id3 protein plays a crucial role in directing blood cell progenitors to become gamma-delta T cells. These unique cells possess attributes of both the adaptive and innate arms of the immune system, providing enhanced protection against infections and diseases.
Researchers have found that tumor cells release microvesicles that stimulate the growth of blood vessels, allowing tumors to grow. A new molecule called Diannexin has been identified as a potential therapeutic agent that can block this process and starve tumors.
Researchers at Tel Aviv University discovered that transfusions of 'young' blood –– blood stored for less than 9 days –– increased the odds of survival in animals with leukemia and breast cancer. Fresh blood may be a game-changer in cancer treatment, potentially improving survival rates.
Novel treatments, including fostamatinib disodium, have shown significant clinical activity in treating leukemia and lymphoma. The study found improved response rates and prolonged stable disease in patients with relapsed or refractory B-cell non-Hodgkin lymphoma.
A team of Stanford researchers has created a prototype blood scanner that can detect cancer biomarkers in the bloodstream at an early stage of the disease. The system uses magnetic nanotechnology to spot cancer proteins, which is tens to hundreds of times more sensitive than existing commercial devices. This technology holds promise fo...
Researchers found blood transfusions in hospitalized cancer patients increased venous thromboembolism (VTE) and arterial thromboembolism (ATE) rates, comparable to erythropoiesis-stimulating agents (ESAs). This study highlights the need for cautious use of transfusions and exploration of ways to reduce clot risk in cancer patients.
Researchers found that the use of predictive biomarkers and targeted therapies significantly delayed the need for conventional chemotherapy in patients with early-stage but high-risk chronic lymphoid leukemia (CLL). The study resulted in a four-year delay in treatment compared to two years, showing promising results for personalized care.
A landmark clinical trial is underway to test whether a low-molecule-weight heparin can prevent pulmonary embolism in patients receiving chemotherapy on an outpatient basis. The trial aims to identify high-risk cancer patients and demonstrate that blood clots can be prevented with anti-coagulant therapy.